Inovio Pharma (INO) Misses Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.11 -0.89%
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AXT appoints Tracy Liu to its board of directors
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
